PRESS RELEASE: Plexus Research targets the 3D of Clinical Trials by building the largest clinical trial network in South Australia.
Plexus Research has created the largest clinical trial network in South Australia in one year targeting drugs, devices, and digital solutions (3D) for Australian and global companies. In less than a year, Plexus has created a network of 10 clinics, 40 GPs as investigators and a 100,000 database of active patients. Through our parent company GP Partners Australia, we have access to grow our network to 1600 GPs, 400+ clinics and covers majority of the 1.3 million population of Adelaide.
Plexus provides a clinical and commercial path to market for small biotechs, digital health start-ups, MedTech devices and large pharmaceutical companies.
Working with a network of GP and Specialist clinics we have created a platform that enables path breaking medical products to find scientific and market data in the community and reach to potential participants easily.
New Board
Plexus Research is announcing its board led by Roseanne Healy as the Chair, Tam C Nguyen as a non-executive Director and Suhit Anantula as the Executive Director and CEO.
Roseanne brings to Plexus Research over 20 years corporate experience on mergers, acquisitions, capital raising and turnarounds; informed by investment banking, venture capital and start up roles over the course of her career.
Associate Professor Tam Nguyen has over 20 years of working in the healthcare, health and medical research environment including tertiary teaching hospitals and research institute across Australia. His current and previous senior roles cover research strategy, research ethics and governance, clinical trials, research innovation and development.
Suhit is an award winning global strategic design leader with experience in working across Australia, Asia, Europe and US. In his various roles he has worked in global multinationals like ADP, start-ups like Deeshaa, NFPs like TACSI, in the public sector, small business and a consultant across the world in various industries and organisations.
Suhit Anantula says, “By connecting a diverse network of clinics, GPs and patient populations we can solve the number one key challenge in clinical trials – on time recruitment”!
Post-Covid Opportunity
In 2019, more than 50,000 trials were conducted globally. According to some estimates, about 80% of all non-Covid trials have stopped or interrupted in 2020. In 2021 and 2022 we will see a huge increase in clinical trials and Plexus aims to capture that opportunity.
Covid has created a larger need for digital health which is a $200B market globally. By providing a commercial and clinical path to market for startups Plexus creates value in this fast growing market.
###
About Plexus Research:
We are a community-based drug development partner with a rich and diverse SMO network in Adelaide, Australia.
With access to a unique network of GP Investigators and patient populations, and best-in-class technology platform partners, Plexus Research offers end-to-end clinical trials services to local and international pharmaceutical, biotech, MedTech, digital health and clinical research organisations.
For Contact
Suhit Anantula
Founder & CEO
Plexus Research
We connect sponsors with sites and participants by reimagining the clinical trial process
E: [email protected]
W: https://www.plexusresearch.com.au
M: 0492 908 112
